Cover Image
市場調查報告書

末梢動脈閉塞性疾病(PAOD):開發平台分析

Peripheral Artery Occlusive Disease (PAOD) - Pipeline Review, H2 2015

出版商 Global Markets Direct 商品編碼 251608
出版日期 內容資訊 英文 236 Pages
訂單完成後即時交付
價格
Back to Top
末梢動脈閉塞性疾病(PAOD):開發平台分析 Peripheral Artery Occlusive Disease (PAOD) - Pipeline Review, H2 2015
出版日期: 2015年09月23日 內容資訊: 英文 236 Pages
簡介

末梢動脈閉塞性疾病(PAOD)指的是位於心臟與腦外側的血管(動、靜脈)的疾病。常見的症狀有伴隨步行及上樓梯等運動後股關節、大腿或小腿肌肉酸痛的痙攣(間歇性跛行)、腳部發麻或衰弱、尤其和其他部位比較下小腿或腳發冷、腳尖疼痛、足腿傷口難癒、腳趾指甲生長慢,及男性的勃起障礙(ED)等。

本報告提供末梢動脈閉塞性疾病(PAOD)的治療藥開發情形調查分析,提供您開發中產品的概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

目錄

簡介

末梢動脈閉塞性疾病(PAOD)概要

治療藥的開發

  • 開發中產品:概要
  • 開發中產品:比較分析

開發中的治療藥:各企業

開發中產品的概要

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品
  • 開發階段不明的產品

開發中的產品:各企業

開發治療藥的企業

  • Alvogen Korea
  • AnGes MG, Inc.
  • Annexin Pharmaceuticals AB
  • Apceth GmbH & Co. KG
  • AstraZeneca Plc
  • Athersys, Inc.
  • Bayer AG
  • Betagenon AB
  • Cardiolynx AG
  • CardioVascular BioTherapeutics, Inc.
  • Celgene Corporation
  • Cytokinetics, Inc.
  • Diffusion Pharmaceuticals LLC
  • DNAVEC Corporation
  • Eli Lilly and Company
  • Grifols, S.A.
  • Juventas Therapeutics, Inc.
  • 興和
  • Lacer, S.A.
  • LTT Bio-Pharma Co., Ltd.
  • MedImmune, LLC
  • miRagen Therapeutics, Inc.
  • Multi Gene Vascular Systems Ltd
  • Nuo Therapeutics, Inc.
  • Pluristem Therapeutics Inc.
  • Proteon Therapeutics, Inc.
  • Recardio GmbH
  • RegenoCELL Therapeutics, Inc.
  • Resverlogix Corp.
  • Sagene Pharmaceuticals, Inc.
  • Stemedica Cell Technologies, Inc.
  • Symic Biomedical, Inc.
  • Theravasc, Inc.
  • vasopharm GmbH
  • ViroMed Co., Ltd.
  • Yuyu Pharma, Inc.

治療藥的評估

  • 單獨療法的情況
  • 聯合治療的情況
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介(產品說明/作用機制/R&D進展)

  • (cilostazol + organic nitrate) ER
  • AEM-28
  • ALD-301
  • Alecmestencel-T
  • Annexin A-5
  • AP-01
  • apabetalone
  • beperminogene perplasmid
  • CVBT-141C
  • DVC1-0101
  • ELS-140
  • evacetrapib
  • 危急性肢體缺血·末梢動脈閉塞性疾病(PAOD)基因治療
  • Human Plasmin
  • JVS-100
  • K-134
  • LA-419
  • LT-0101
  • MEDI-6012
  • 間充織幹細胞
  • MGN-6114
  • MultiGeneAngio
  • MultiGeneGraft
  • MultiStem
  • O-304
  • PDA-002
  • PLX-PAD
  • REC-03
  • rivaroxaban
  • sarpogrelate SR
  • SBCV-030
  • selegiline + Antiplatelet Drugs
  • sodium nitrite SR
  • 循環系統系疾病幹細胞治療
  • ticagrelor
  • tirasemtiv
  • transcrocetinate sodium
  • TXA-127
  • VAS-2870
  • VM-202
  • vonapanitase
  • YY-984

開發中產品的最新趨勢

暫停的計劃

開發中止的產品

產品開發的里程碑

  • 值得注意的最新趨勢·新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC7084IDB

Summary

Global Markets Direct's, 'Peripheral Artery Occlusive Disease (PAOD) - Pipeline Review, H2 2015', provides an overview of the Peripheral Artery Occlusive Disease (PAOD)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Peripheral Artery Occlusive Disease (PAOD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Peripheral Artery Occlusive Disease (PAOD) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Peripheral Artery Occlusive Disease (PAOD)
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Peripheral Artery Occlusive Disease (PAOD) and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Peripheral Artery Occlusive Disease (PAOD) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Peripheral Artery Occlusive Disease (PAOD) pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Peripheral Artery Occlusive Disease (PAOD)
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Peripheral Artery Occlusive Disease (PAOD) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Peripheral Artery Occlusive Disease (PAOD) Overview
  • Therapeutics Development
    • Pipeline Products for Peripheral Artery Occlusive Disease (PAOD) - Overview
    • Pipeline Products for Peripheral Artery Occlusive Disease (PAOD) - Comparative Analysis
  • Peripheral Artery Occlusive Disease (PAOD) - Therapeutics under Development by Companies
  • Peripheral Artery Occlusive Disease (PAOD) - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
    • Unknown Stage Products
  • Peripheral Artery Occlusive Disease (PAOD) - Products under Development by Companies
  • Peripheral Artery Occlusive Disease (PAOD) - Companies Involved in Therapeutics Development
    • Alvogen Korea
    • AnGes MG, Inc.
    • Annexin Pharmaceuticals AB
    • Apceth GmbH & Co. KG
    • AstraZeneca Plc
    • Athersys, Inc.
    • Bayer AG
    • Betagenon AB
    • Cardiolynx AG
    • CardioVascular BioTherapeutics, Inc.
    • Celgene Corporation
    • Cytokinetics, Inc.
    • Diffusion Pharmaceuticals LLC
    • DNAVEC Corporation
    • Eli Lilly and Company
    • Grifols, S.A.
    • Juventas Therapeutics, Inc.
    • Kowa Company, Ltd.
    • Lacer, S.A.
    • LTT Bio-Pharma Co., Ltd.
    • MedImmune, LLC
    • miRagen Therapeutics, Inc.
    • Multi Gene Vascular Systems Ltd
    • Nuo Therapeutics, Inc.
    • Pluristem Therapeutics Inc.
    • Proteon Therapeutics, Inc.
    • Recardio GmbH
    • RegenoCELL Therapeutics, Inc.
    • Resverlogix Corp.
    • Sagene Pharmaceuticals, Inc.
    • Stemedica Cell Technologies, Inc.
    • Symic Biomedical, Inc.
    • Theravasc, Inc.
    • vasopharm GmbH
    • ViroMed Co., Ltd.
    • Yuyu Pharma, Inc.
  • Peripheral Artery Occlusive Disease (PAOD) - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • (cilostazol + organic nitrate) ER - Drug Profile
    • AEM-28 - Drug Profile
    • ALD-301 - Drug Profile
    • Alecmestencel-T - Drug Profile
    • Annexin A-5 - Drug Profile
    • AP-01 - Drug Profile
    • apabetalone - Drug Profile
    • beperminogene perplasmid - Drug Profile
    • CVBT-141C - Drug Profile
    • DVC1-0101 - Drug Profile
    • ELS-140 - Drug Profile
    • evacetrapib - Drug Profile
    • Gene Therapy for Critical Limb Ischemia and Peripheral Arterial Disease - Drug Profile
    • Human Plasmin - Drug Profile
    • JVS-100 - Drug Profile
    • K-134 - Drug Profile
    • LA-419 - Drug Profile
    • LT-0101 - Drug Profile
    • MEDI-6012 - Drug Profile
    • Mesenchymal Stem Cells - Drug Profile
    • MGN-6114 - Drug Profile
    • MultiGeneAngio - Drug Profile
    • MultiGeneGraft - Drug Profile
    • MultiStem - Drug Profile
    • O-304 - Drug Profile
    • PDA-002 - Drug Profile
    • PLX-PAD - Drug Profile
    • REC-03 - Drug Profile
    • rivaroxaban - Drug Profile
    • sarpogrelate SR - Drug Profile
    • SBCV-030 - Drug Profile
    • selegiline + Antiplatelet Drugs - Drug Profile
    • sodium nitrite SR - Drug Profile
    • Stem Cell Therapy for Cardiovascular Diseases - Drug Profile
    • ticagrelor - Drug Profile
    • tirasemtiv - Drug Profile
    • transcrocetinate sodium - Drug Profile
    • TXA-127 - Drug Profile
    • VAS-2870 - Drug Profile
    • VM-202 - Drug Profile
    • vonapanitase - Drug Profile
    • YY-984 - Drug Profile
  • Peripheral Artery Occlusive Disease (PAOD) - Recent Pipeline Updates
  • Peripheral Artery Occlusive Disease (PAOD) - Dormant Projects
  • Peripheral Artery Occlusive Disease (PAOD) - Discontinued Products
  • Peripheral Artery Occlusive Disease (PAOD) - Product Development Milestones
    • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Peripheral Artery Occlusive Disease (PAOD), H2 2015
  • Number of Products under Development for Peripheral Artery Occlusive Disease (PAOD) - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Number of Products under Development by Companies, H2 2015 (Contd..1)
  • Number of Products under Development by Companies, H2 2015 (Contd..2)
  • Comparative Analysis by Late Stage Development, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Development, H2 2015
  • Comparative Analysis by Unknown Stage Development, H2 2015
  • Products under Development by Companies, H2 2015
  • Products under Development by Companies, H2 2015 (Contd..1)
  • Products under Development by Companies, H2 2015 (Contd..2)
  • Products under Development by Companies, H2 2015 (Contd..3)
  • Peripheral Artery Occlusive Disease (PAOD) - Pipeline by Alvogen Korea, H2 2015
  • Peripheral Artery Occlusive Disease (PAOD) - Pipeline by AnGes MG, Inc., H2 2015
  • Peripheral Artery Occlusive Disease (PAOD) - Pipeline by Annexin Pharmaceuticals AB, H2 2015
  • Peripheral Artery Occlusive Disease (PAOD) - Pipeline by Apceth GmbH & Co. KG, H2 2015
  • Peripheral Artery Occlusive Disease (PAOD) - Pipeline by AstraZeneca Plc, H2 2015
  • Peripheral Artery Occlusive Disease (PAOD) - Pipeline by Athersys, Inc., H2 2015
  • Peripheral Artery Occlusive Disease (PAOD) - Pipeline by Bayer AG, H2 2015
  • Peripheral Artery Occlusive Disease (PAOD) - Pipeline by Betagenon AB, H2 2015
  • Peripheral Artery Occlusive Disease (PAOD) - Pipeline by Cardiolynx AG, H2 2015
  • Peripheral Artery Occlusive Disease (PAOD) - Pipeline by CardioVascular BioTherapeutics, Inc., H2 2015
  • Peripheral Artery Occlusive Disease (PAOD) - Pipeline by Celgene Corporation, H2 2015
  • Peripheral Artery Occlusive Disease (PAOD) - Pipeline by Cytokinetics, Inc., H2 2015
  • Peripheral Artery Occlusive Disease (PAOD) - Pipeline by Diffusion Pharmaceuticals LLC, H2 2015
  • Peripheral Artery Occlusive Disease (PAOD) - Pipeline by DNAVEC Corporation, H2 2015
  • Peripheral Artery Occlusive Disease (PAOD) - Pipeline by Eli Lilly and Company, H2 2015
  • Peripheral Artery Occlusive Disease (PAOD) - Pipeline by Grifols, S.A., H2 2015
  • Peripheral Artery Occlusive Disease (PAOD) - Pipeline by Juventas Therapeutics, Inc., H2 2015
  • Peripheral Artery Occlusive Disease (PAOD) - Pipeline by Kowa Company, Ltd., H2 2015
  • Peripheral Artery Occlusive Disease (PAOD) - Pipeline by Lacer, S.A., H2 2015
  • Peripheral Artery Occlusive Disease (PAOD) - Pipeline by LTT Bio-Pharma Co., Ltd., H2 2015
  • Peripheral Artery Occlusive Disease (PAOD) - Pipeline by MedImmune, LLC, H2 2015
  • Peripheral Artery Occlusive Disease (PAOD) - Pipeline by miRagen Therapeutics, Inc., H2 2015
  • Peripheral Artery Occlusive Disease (PAOD) - Pipeline by Multi Gene Vascular Systems Ltd, H2 2015
  • Peripheral Artery Occlusive Disease (PAOD) - Pipeline by Nuo Therapeutics, Inc., H2 2015
  • Peripheral Artery Occlusive Disease (PAOD) - Pipeline by Pluristem Therapeutics Inc., H2 2015
  • Peripheral Artery Occlusive Disease (PAOD) - Pipeline by Proteon Therapeutics, Inc., H2 2015
  • Peripheral Artery Occlusive Disease (PAOD) - Pipeline by Recardio GmbH, H2 2015
  • Peripheral Artery Occlusive Disease (PAOD) - Pipeline by RegenoCELL Therapeutics, Inc., H2 2015
  • Peripheral Artery Occlusive Disease (PAOD) - Pipeline by Resverlogix Corp., H2 2015
  • Peripheral Artery Occlusive Disease (PAOD) - Pipeline by Sagene Pharmaceuticals, Inc., H2 2015
  • Peripheral Artery Occlusive Disease (PAOD) - Pipeline by Stemedica Cell Technologies, Inc., H2 2015
  • Peripheral Artery Occlusive Disease (PAOD) - Pipeline by Symic Biomedical, Inc., H2 2015
  • Peripheral Artery Occlusive Disease (PAOD) - Pipeline by Theravasc, Inc., H2 2015
  • Peripheral Artery Occlusive Disease (PAOD) - Pipeline by vasopharm GmbH, H2 2015
  • Peripheral Artery Occlusive Disease (PAOD) - Pipeline by ViroMed Co., Ltd., H2 2015
  • Peripheral Artery Occlusive Disease (PAOD) - Pipeline by Yuyu Pharma, Inc., H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Assessment by Combination Products, H2 2015
  • Number of Products by Stage and Target, H2 2015
  • Number of Products by Stage and Mechanism of Action, H2 2015
  • Number of Products by Stage and Route of Administration, H2 2015
  • Number of Products by Stage and Molecule Type, H2 2015
  • Peripheral Artery Occlusive Disease (PAOD) Therapeutics - Recent Pipeline Updates, H2 2015
  • Peripheral Artery Occlusive Disease (PAOD) - Dormant Projects, H2 2015
  • Peripheral Artery Occlusive Disease (PAOD) - Dormant Projects (Contd..1), H2 2015
  • Peripheral Artery Occlusive Disease (PAOD) - Dormant Projects (Contd..2), H2 2015
  • Peripheral Artery Occlusive Disease (PAOD) - Dormant Projects (Contd..3), H2 2015
  • Peripheral Artery Occlusive Disease (PAOD) - Dormant Projects (Contd..4), H2 2015
  • Peripheral Artery Occlusive Disease (PAOD) - Discontinued Products, H2 2015
  • Peripheral Artery Occlusive Disease (PAOD) - Discontinued Products (Contd..1), H2 2015

List of Figures

  • Number of Products under Development for Peripheral Artery Occlusive Disease (PAOD), H2 2015
  • Number of Products under Development for Peripheral Artery Occlusive Disease (PAOD) - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Comparative Analysis by Late Stage Development, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Products, H2 2015
  • Comparative Analysis by Unknown Stage Development, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Top 10 Targets, H2 2015
  • Number of Products by Stage and Top 10 Targets, H2 2015
  • Number of Products by Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Top 10 Routes of Administration, H2 2015
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2015
  • Number of Products by Top 10 Molecule Types, H2 2015
  • Number of Products by Stage and Top 10 Molecule Types, H2 2015
Back to Top